Globus Medical, Inc. (GMED)

NYSE: GMED · IEX Real-Time Price · USD
55.27
+1.80 (3.37%)
Mar 30, 2023, 10:01 AM EDT - Market open
3.37%
Market Cap 5.57B
Revenue (ttm) 1.02B
Net Income (ttm) 190.17M
Shares Out 100.31M
EPS (ttm) 1.85
PE Ratio 28.90
Forward PE 32.26
Dividend n/a
Ex-Dividend Date n/a
Volume 214,917
Open 54.80
Previous Close 53.47
Day's Range 54.55 - 55.27
52-Week Range 50.92 - 81.78
Beta 1.05
Analysts Buy
Price Target 68.51 (+23.96%)
Earnings Date May 8, 2023

About GMED

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspi... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Aug 3, 2012
Employees 2,400
Stock Exchange NYSE
Ticker Symbol GMED
Full Company Profile

Financial Performance

In 2022, Globus Medical's revenue was $1.02 billion, an increase of 6.76% compared to the previous year's $958.10 million. Earnings were $190.17 million, an increase of 27.47%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for GMED stock is "Buy." The 12-month stock price forecast is $68.51, which is an increase of 23.96% from the latest price.

Price Target
$68.51
(23.96% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NUVASIVE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NuVasive, Inc. - NUVA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NuVasive, Inc. (...

Other symbols: NUVA
18 hours ago - Business Wire

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs

The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

5 days ago - Zacks Investment Research

Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises

Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.

1 month ago - Zacks Investment Research

Globus Medical (GMED) Tops Q4 Earnings Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 7.27% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Globus Medical Reports Fourth Quarter and Full Year 2022 Results

AUDUBON, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year en...

1 month ago - GlobeNewsWire

Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

NUVASIVE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NuVasive, Inc. - NUVA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NuVasive, Inc. (...

Other symbols: NUVA
1 month ago - Business Wire

Top 5 Health Care Stocks That Could Blast Off This Month - Azenta (NASDAQ:AZTA), Amgen (NASDAQ:AMGN)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AMGNAZTAZYXI
1 month ago - Benzinga

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of NuVasive, Inc.

NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by NuVasive, Inc. (NASDAQ: NUVA) and its board of directors concerning the proposed acquisi...

Other symbols: NUVA
1 month ago - PRNewsWire

GMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Globus Medical, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Globus Medical, Inc. (NYSE: GMED) and NuVasive, Inc. is fair to Globus shareholders. Un...

1 month ago - Business Wire

Globus Medical to Buy NuVasive in $3.1 Billion Deal

The implied price for NuVasive under terms of the deal is $57.72 a share.

Other symbols: NUVA
1 month ago - Barrons

NuVasive rallies while Globus Medical moves down after companies announce all-stock merger deal

Globus Medical GMED, -1.18% said Thursday it will pay 0.75 a share of its stock for each share of NuVasive NUVA, -2.41% stock in a deal that values NuVasive at about $3.1 billion or $57.72 a share. Gl...

Other symbols: NUVA
1 month ago - Market Watch

Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care

Capitalizes on complementary global commercial organizations and accelerates Globus Medical's and NuVasive's globalization strategies to increase customer reach and deepen surgeon relationships Brings...

Other symbols: NUVA
1 month ago - PRNewsWire

Globus Medical Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

AUDUBON, Pa., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ...

1 month ago - GlobeNewsWire

Here's Why Investors Should Retain Globus Medical (GMED) Stock

Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.

2 months ago - Zacks Investment Research

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market ...

3 months ago - Zacks Investment Research

Globus Medical Partners with the UK's NHS to Provide Hospitals with Surgical Robotic Navigation Technology

First Robotic Assisted Spine Surgeries Performed at Two NHS Trust Hospitals with Globus Medical's ExcelsiusGPS® First Robotic Assisted Spine Surgeries Performed at Two NHS Trust Hospitals with Globus ...

4 months ago - GlobeNewsWire

Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut

Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.

4 months ago - Zacks Investment Research

Globus Medical (GMED) Q3 Earnings Lag Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of -3.85% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Globus Medical Reports Third Quarter 2022 Results

AUDUBON, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30...

5 months ago - GlobeNewsWire

Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Globus Medical Schedules Third Quarter Earnings Release and Conference Call

AUDUBON, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September...

5 months ago - GlobeNewsWire

Here's Why Investors Should Retain Globus Medical (GMED) For Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.

6 months ago - Zacks Investment Research

Globus Medical (GMED) Gains Market Share, Cost Woes Stay

Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.

7 months ago - Zacks Investment Research

Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips

Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.

8 months ago - Zacks Investment Research